

**Supplementary Table S1.** Classification of antibiotic agents into their respective antibiotic class.

Antibiotic class	Antibiotic agent
Aminoglycosides	Gentamicin Amikacin Paromomycin
Carbapenems	Ertapenem Imipenem Meropenem
Extended spectrum cephalosporines	Cefotaxime Ceftazidime Cefepime Ceftriaxone Ceftazidime/Avibactam Cefoperazone Ceftolozane/Tazobactam
Glycopeptides	Vancomycin Teicoplanin
Daptomycin	Daptomycin
Linezolid	Linezolid
Penicillin	Amoxicillin/Clavulanic acid Ampicillin/Sulbactam Piperacillin/Tazobactam
Colistin	Colistin

**Supplementary Table S2.** Multinomial logistic regression model for *A. baumannii* colonization or infection among SARS-CoV-2 patients admitted to the intensive care unit of the Umberto I teaching hospital of Rome between 1 March 2020 and 28 February 2021.

	Colonization by <i>A. baumannii</i>		Infection by <i>A. baumannii</i>	
	RRR (95% CI)	p-Value	RRR (95% CI)	p-Value
Age (years)	0.99 (0.96-1.02)	0.399	1.03 (0.98-1.07)	0.246
Sex (male)	1.02 (0.45-2.30)	0.959	1.72 (0.64-4.60)	0.283
Pre-existing comorbidity (yes)	1.00 (0.46-2.20)	0.993	0.60 (0.22-1.62)	0.311
SAPS II score	1.00 (0.96-1.04)	0.845	0.93 (0.87-0.99)	0.016
Mechanical ventilation, days	1.00 (0.95-1.05)	0.929	1.04 (0.98-1.10)	0.213
Previous consumption of carbapenems (yes)	4.36 (1.67-11.39)	0.003	4.05 (1.24-13.20)	0.020
Previous consumption of extended spectrum cephalosporins (yes)	1.46 (0.57-3.72)	0.430	0.36 (0.07-1.81)	0.215
Previous consumption of glycopeptides (yes)	0.69 (0.29-1.63)	0.403	1.17 (0.39-3.51)	0.780
Previous consumption of macrolides (yes)	1.97 (0.92-4.23)	0.080	1.49 (0.55-4.01)	0.429
Previous consumption of oxazolidinones (yes)	0.60 (0.16-2.34)	0.465	1.93 (0.44-8.50)	0.385
Previous consumption of penicillins (yes)	1.25 (0.54-2.86)	0.605	0.66 (0.22-1.96)	0.453

RRR: Relative Risk Ratio. CI: Confidence Interval. SAPS: Simplified Acute Physiology Score.